Entrada Therapeutics Inc. (TRDA) Live Share Price, Invest From India

Entrada Therapeutics Inc. Stock Performance

as on June 17, 2026 at 2:16 pm IST

Day's Low
Day's High
$6.35
Day's Price Range
$6.62
$6.50
2.31%
Downside
1.85%
Upside
52 Week's Low
52 Week's High
$4.93
52-Week Price Range
$16.45
$6.50
24.15%
Downside
153.08%
Upside

Entrada Therapeutics Inc. share price movements today

Previous Close: $6.58
Open: $6.53
Volume: 233.7K
Day's Low - High: $6.35 - $6.62
52 Week Low - High: $4.93 - $16.45

Entrada Therapeutics Inc. Historical Returns

1 Month Return: + 1.88 %
3 Month Return: -48.37 %
1 Year Return: -9.85 %
3 Year Return: -56.23 %
5 Year Return: 0 %

Entrada Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Entrada Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$256.2M

EPS (TTM)

-3.7943

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-172.6M

Revenue (TTM)

5.7M

Profit Margin

0.00%

Return On Equity TTM

-48.28%

Entrada Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Entrada Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Entrada Therapeutics Inc.	BUY	$256.2M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Common Stock	BUY	$38.4B	63.66%	72.49	12.55%	NA
Vertex PharmaceuticalsCommon Stock	BUY	$114.3B	140.59%	26.73	35.51%	NA
Regeneron Pharmaceuticals Common Stock	BUY	$64.5B	14.69%	15.02	29.65%	0.58%

Stock Returns calculator for Entrada Therapeutics Inc. Stock including INR - Dollar returns

The Entrada Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Entrada Therapeutics Inc. investment value today

Current value as on today

₹99,294

Returns

-₹706

(-0.71%)

Returns from Entrada Therapeutics Inc. Stock

-₹9,847 (-9.85%)

Dollar Impact

₹9,141 (+9.14%)

Analyst Recommendation on Entrada Therapeutics Inc. Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Entrada Therapeutics Inc.. Average target price of $18.75

Entrada Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Entrada Therapeutics Inc..

What analysts predicted

65.33%UPSIDE

Target Price

$18.75

Current Price

$6.5

Analyzed by

10 Analysts

Target

$18.75

Entrada Therapeutics Inc. target price $18.75, a slight upside of 65.33% compared to current price of $6.5. According to 10 analysts rating.

Indian Investors' Interest in Entrada Therapeutics Inc. Stock

Search interest for Entrada Therapeutics Inc. Stock has increased by 693% in the last 30 days, reflecting an upward trend in search activity.

Time period: May 18, 2026 to June 17, 2026

Change:693% versus previous 30 day period

Entrada Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	41	59	94	19	37	20	1	1	1	0
Gross Profit	41	59	94	19	37	20	1	-36	0	0
Operating Income	4	21	53	-21	-5	-21	-46	-47	-42	-42
EBITDA	9	26	58	-14	0	-16	-41	-42	-41	-38
Interest Expense	4	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	1	1	0	0
Income Before Tax	9	25	57	-15	0	-17	-42	-43	-39	-39
Income Tax Expense	18	1	2	-1	-1	-	0	0	0	0
Net Income	-9	23	55	-14	1	-17	-43	-44	-39	-39
Net Profit Margin	-22.81%	39.74%	58.11%	-71.70%	3.02%	-84.39%	-2210.41%	-2734.45%	-3014.93%	-4539.09%

Entrada Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	25	129	210	25
Gross Profit	0	0	-1	-1	129	210	21
Operating Income	-11	-26	-51	-97	-3	47	-155
EBITDA	-11	-26	-50	-95	14	70	-142
Interest Expense	-	-	0	2	-	-	-
Depreciation	0	0	1	1	2	3	4
Income Before Tax	-5	-26	-51	-94	12	66	-142
Income Tax Expense	0	0	-1	-7	18	0	0
Net Income	-4	-26	-50	-87	-6	65	-143
Net Profit Margin	0.00%	0.00%	0.00%	-346.23%	-5.18%	31.13%	-565.48%

Entrada Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	23	55	-14	1	-17	-43	-44	-39	-39
Operating Cash Flow	-25	39	-24	-31	-38	-29	-28	-32	-41
Investing Cash Flow	26	-24	-82	53	4	33	49	29	26
Financing Cash Flow	0	101	0	1	0	0	0	0	0
Change in Cash	0	116	-107	23	-33	4	20	-2	-14

Entrada Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-26	-51	-94	-6	65	-143
Operating Cash Flow	-25	-50	-93	139	-41	-128
Investing Cash Flow	-2	-4	-148	-138	-27	116
Financing Cash Flow	50	307	0	21	102	0
Change in Cash	22	252	-245	22	33	-10

Global Institutional Holdings in Entrada Therapeutics Inc.

Funds	Holdings
Dimensional Fund Advisors, Inc.	0.84%
Baker Bros Advisors LP	13.07%
TCG Crossover Management, LLC	5.89%
Charles Schwab Investment Management Inc	0.55%
State Street Corp	1.38%

See all

Insights on Entrada Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 20.8% return, outperforming this stock by 30.6%
NO EFFECT
Against Peers
In the last 3 years, Entrada Therapeutics, Inc. Common Stock has experienced a drawdown of -56.2%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 34.7%
NEGATIVE IMPACT
Price Dip
In the last 3 months, TRDA stock has moved down by -48.4%

About Entrada Therapeutics Inc.

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Organisation	Entrada Therapeutics Inc.
Headquarters	One Design Center Place, Boston, MA, United States, 02210
Industry	Biotechnology
CEO	Mr. Dipal Doshi
E-voting on shares	Click here to vote

Key Management of Entrada Therapeutics Inc.

Name	Title
Mr. Dipal Doshi	CEO & Director
Dr. Natarajan Sethuraman Ph.D.	President of Research & Development
Ms. Karla MacDonald	Chief Corporate Affairs Officer
Sandeep Basnet	Head of Information Technology
Mr. Nathan J. Dowden	President & COO
Mr. Kory James Wentworth CPA	CFO & Treasurer
Dr. Jared Cohen J.D., Ph.D.	General Counsel
Ms. Kerry Robert M.S.	Senior Vice President of People
Mr. Kevin Healy Ph.D.	Senior Vice President of Regulatory Affairs

FAQs

What is Entrada Therapeutics Inc. share price today?

Entrada Therapeutics Inc. share price today is $6.5 as on June 17, 2026 at 8:46 am IST at the close of the market. Entrada Therapeutics Inc. share today touched a day high of $6.62 and a low of $6.35.

What is the 52 week high and 52 week low for Entrada Therapeutics Inc. share?

Entrada Therapeutics Inc. share touched a 52 week high of $16.45 on May 6, 2026 and a 52 week low of $4.93 on August 11, 2025. Entrada Therapeutics Inc. stock price today i.e. June 17, 2026 at 8:46 am IST is closed at $6.5,which is 60.49% down from its 52 week high and 31.85% up from its 52 week low.

What is Entrada Therapeutics Inc.'s market capitalisation today?

Entrada Therapeutics Inc. market capitalisation is $0.00T as on June 17, 2026 at 8:46 am IST.

How to invest in Entrada Therapeutics Inc. Stock (TRDA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Entrada Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Entrada Therapeutics Inc. Shares that will get you 0.2308 shares as per Entrada Therapeutics Inc. share price of $6.5 per share as on June 17, 2026 at 8:46 am IST.

What is the minimum amount required to buy Entrada Therapeutics Inc. Stock (TRDA) from India?

Indian investors can start investing in Entrada Therapeutics Inc. (TRDA) shares with as little as ₹94.55 or $1 (as of June 17, 2026 at 3:11 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹945.50 in Entrada Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on June 17, 2026 at 3:11 pm IST). Based on Entrada Therapeutics Inc. share’s latest price of $6.5 as on June 17, 2026 at 8:46 am IST, you will get 1.5385 shares of Entrada Therapeutics Inc.. Learn more about fractional shares .